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OBJECTIVES The purpose of this study was to examine whether endogenous estrogen deficiency induced
by ovariectomy affects chronic left ventricular dysfunction post–myocardial infarction (MI).
BACKGROUND Epidemiologic findings suggest that mortality of postmenopausal women is increased after
MI, but the underlying mechanisms are unknown.
METHODS Rats were either not ovariectomized (non-OVX), ovariectomized (OVX) or ovariectomized
and treated with subcutaneous 17-beta-estradiol (E2) pellets (OVX 1 E2). Two weeks later,
animals were sham-operated (Sham) or left coronary artery ligated (MI). Eight weeks later,
in vivo echocardiographic and hemodynamic measurements were performed. Thereafter,
hearts were isolated and perfused isovolumically.
RESULTS Mean infarct size was similar among the three MI groups. Ovariectomy decreased serum E2
levels (11 6 4 vs. 49 6 11 pg/ml in non-OVX, p , 0.01) and increased body weight. These
changes were reversed by E2 replacement. The degree of cardiac hypertrophy was similar for
all groups post-MI. Left ventricular diameters were increased post-MI (8.9 6 0.4 in
non-OVX 1 MI vs. 6.7 6 0.2 mm in non-OVX 1 Sham hearts, p , 0.0001), but OVX or
OVX 1 E2 replacement did not alter left ventricular diameters in post-MI and Sham hearts.
Left ventricular fractional shortening was severely impaired post-MI (19 6 2% vs. 50 6 3 in
non-OVX 1 Sham hearts, p , 0.0001) with no influence of hormonal status. Left ventricular
end-diastolic pressure, measured in vivo, was increased in all MI groups without significant
differences between groups. Pressure-volume curves, obtained in perfused hearts, demon-
strated a right and downward shift with reduced maximum left ventricular developed pressure
post-MI (75 6 6 vs. 108 6 3 mm Hg in non-OVX 1 Sham hearts, p , 0.001) and were
also unaffected by either OVX or E2 replacement.
CONCLUSIONS Chronic endogenous estrogen deficiency does not have major effects on the development of
cardiac hypertrophy, dysfunction and dilation post-MI. (J Am Coll Cardiol 1999;34:
1427–34) © 1999 by the American College of Cardiology
The incidence of cardiovascular disease in premenopausal
women is lower compared with age-matched men but
increases rapidly after menopause up to a level close to that
in men (1). Premenopausal women appear to be protected
from the development of coronary artery disease, and after
menopause, estrogen replacement therapy reduces the inci-
dence of coronary artery disease and the progression of
coronary artery lesions (2–6). In postmenopausal women,
prognosis post–myocardial infarction (MI) is inferior to that
in males (7–12). Furthermore, epidemiologic data (13)
suggest that death from MI is less frequent in women
receiving estrogen replacement therapy compared with
women not taking estrogens. The observational studies
published to date (3,4,14,15) have shown that estrogen is
associated with a 70% to 80% lower risk of death in women
with established coronary artery disease.
This cardioprotective effect is generally believed to be
related to the interaction of estrogens in the process of
atherosclerosis (16). Additional protective mechanisms of
estrogens may involve effects on vascular function and
structure of the vessel wall involving numerous cellular and
molecular mechanisms. Estrogens can modulate vascular
function by increasing nitric oxide production via stimula-
tion of endothelial nitric oxide synthase (eNOS) (17) and
via a decrease of endothelin-1 levels (18,19). Furthermore,
17-beta-estradiol (E2) is an inhibitor of vascular smooth
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muscle cell proliferation and migration (20), phenomena
that play a major role in atherosclerotic vascular disease.
Besides scavenging free radicals (21), estrogen interferes
with the renin-angiotensin system by decreasing aortic wall
angiotensin-converting enzyme activity (22) and by down-
regulating angiotensin II receptor subtype 1 expression in
vascular smooth muscle cells (23).
Recent studies (24,25) have demonstrated the presence of
estrogen alpha and beta receptors in cardiac myocytes and
fibroblasts. These estrogen receptors are functional and have
been shown to regulate the expression of specific cardiac
genes such as the progesterone receptor and the gap junc-
tion protein connexin 43 gene (25). These findings suggest
that gender-based and pre- versus postmenopausal differ-
ences in cardiac pathophysiology may in part be due to
direct effects of estrogens on cardiac cells such as myocytes
and fibroblasts, which are involved in the remodeling
process post-MI. Therefore, we hypothesized that post-
menopausal estrogen deficiency has a detrimental effect on
the remodeling process post-MI. In the present study, for
the first time, we examine the effect of estrogen deficiency
on post-MI remodeling in rats.
METHODS
Animals, ovariectomy and estrogen substitution. All
procedures conformed to the Position of the American Heart
Association on Research Animal Use, adopted by the American
Heart Association November 11, 1984. Female Wistar rats
weighing 160 to 180 g (Charles River Deutschland GmbH,
Sulzfeld, Germany) were kept in a 12-h light-dark cycle at
constant temperature and humidity. Animals were given
water and commercial rat chow ad libitum.
Ovariectomies (OVX) or non-ovariectomies (non-OVX)
were performed through dorsal incisions under ether anes-
thesia in 12-week-old rats. Rats were randomly assigned to
one of three subgroups: OVX, non-OVX and OVX 1 E2.
Immediately after OVX, half of the animals received sub-
cutaneous implants of 90-day release pellets containing
1 mg of E2 (OVX 1 E2) (Innovative Research of America,
Sarasota, Florida). The non-OVX group and the other
OVX rats received matching placebo pellets. The sustained
release pellets were designed to maintain E2 serum concen-
trations slightly above the physiologic range. Placebo pellets
contained all the components of the E2 pellets except for the
hormone itself.
Experimental MI. Two weeks after OVX or non-OVX,
MI or sham operations were performed in each group.
Thus, together, six experimental groups were studied: 1)
non-OVX sham operated (non-OVX 1 Sham); 2) non-
OVX infarcted (non-OVX 1 MI); 3) OVX sham operated
(OVX 1 Sham); 4) OVX infarcted (OVX 1 MI); 5) OVX,
estrogen-treated sham operated (OVX 1 E2 1 Sham); and
6) OVX, E2-treated infarcted rats (OVX 1 E2 1 MI). Left
coronary artery ligation was induced by a previously de-
scribed technique (26,27). A left thoracotomy was per-
formed under ether anesthesia and positive pressure venti-
lation. The heart was rapidly exteriorized by applying gentle
pressure on both sides of the thorax. The left coronary artery
was ligated between the pulmonary outflow tract and the
left atrium. The heart was then replaced into the thorax,
lungs were inflated by increasing positive end-expiratory
pressure and the wound was closed immediately. Sham
operation was performed using an identical procedure,
except that the suture was passed under the coronary artery
without ligation. Mortality rate of infarcted rats within the
first 24 h after the operation was 40% to 50%.
Echocardiographic studies. Seven to eight weeks after
MI, all rats underwent transthoracic echo-Doppler exami-
nation. Previous reports have demonstrated the accuracy
and the reproducibility of transthoracic echocardiography in
rats for measuring left ventricle (LV) size and function
(28–30). Briefly, rats were anesthetized with ketamine HCl
(50 mg/kg; Parke-Davis, Berlin, Germany) and xylazine
(10 mg/kg; BayerVital, Leverkusen, Germany), both given
intraperitoneally. The chest was shaved, and rats were
placed prone on a specially designed apparatus. Echocardio-
grams were performed from underneath with a commer-
cially available echocardiographic system (Toshiba SSH-
140A) equipped with a 7.0-MHz phased-array transducer
(Toshiba Medical Systems GmbH, Munich, Germany). A
two-dimensional short-axis view of the LV was obtained at
the level of the papillary muscles. Two-dimensional targeted
M-mode tracings were recorded through the anterior and
posterior LV walls (Fig. 1). End-diastolic and end-systolic
LV internal diameters were measured by the leading-edge
method according to the American Society of Echocardi-
ology (31). Measurements were taken as the average of three
consecutive cardiac cycles.
Two-dimensionally guided pulsed-wave Doppler spectra
of mitral inflow were recorded from an apical four-chamber
view, with the sample volume placed near the tips of the
mitral leaflets and adjusted to the position where velocity
was maximal and the flow pattern was laminar (Fig. 2). In
rats with MI (13 out of 35 rats), no A waves could be seen
above the filter cutoff on the mitral inflow Doppler spectra.
In these cases, peak A-wave velocity was considered to be
5 cm/s (the lowest limit of the high-pass wall filter cutoff on
the Doppler spectral tracing). All rats remained in sinus
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rhythm. Thus, A waves cannot be absent but may be
undetectable below the filter cutoff. Maximum early and late
diastolic flow velocities were derived from mitral inflow
velocities, and LV outflow tract velocimetry was recorded
from five-chamber views. Cardiac output was calculated as:
cardiac output 5 aortic velocity time integral
3 @p~LV outflow tract/2!2# 3 heart rate.
Left ventricular outflow tract diameter was measured at the
base of the aortic leaflets in a parasternal long-axis view. All
Doppler spectra were recorded on paper at 130 mm/s and
analyzed off-line as described previously (29).
In vivo hemodynamic measurements. Eight weeks after
left coronary artery ligation or sham operation, rats were
anesthetized with ether. A polyethylene cannula was in-
serted into the trachea for artificial ventilation. The right
carotid artery was isolated by cut-down, and a 1-mm
micromanometer-tipped catheter (Millar Instruments,
Houston, Texas) was passed retrogradely into the LV, then
withdrawn to the aortic arch under continuous monitoring
of developed pressures via a three-way stopcock (to allow
flushing), with zero adjusted to mid-chest level to determine
baseline on the recorder. Left ventricular systolic and
end-diastolic pressures, mean arterial pressure and heart rate
(HR) were measured under light ether anesthesia and
spontaneous respiration.
Isolated rat heart preparation. Immediately after in vivo
hemodynamic measurements were completed, a transverse
laparotomy and left and right anterolateral thoracotomy
were performed, and the heart was rapidly excised and
immersed in ice-cold buffer. The aorta was dissected free,
and mounted onto a cannula attached to a perfusion
apparatus, as previously described (32). Retrograde perfu-
sion of the heart was begun in the Langendorff mode at a
constant temperature of 37°C and a constant coronary
perfusion pressure of 100 mm Hg. For perfusion, glucose-
Figure 1. Representative M-mode tracings of the short-axis LV in a non-OVX 1 Sham (a), a non-OVX 1 MI (b), an OVX 1 MI (c)
and an OVX 1 E2 1 MI rat (d) eight weeks after left coronary artery ligation. There is increased LV cavity dimension, akinesis and
thinning of anterior wall in all rats with MI.
Figure 2. Left ventricular developed pressure-volume curves for all
experimental groups; *p , 0.017 sham versus corresponding MI. A
right and downward shift of the curve was observed for all MI
groups. (Open circles) Non-OVX 1 Sham, (filled circles) non-
OVX 1 MI, (open triangles) OVX 1 Sham, (filled triangles)
OVX 1 MI, (open squares) OVX 1 E2 1 Sham, (filled squares)
OVX 1 E2 1 MI.
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containing Krebs-Henseleit buffer was used as previously
described (33). Coronary flow was continuously measured
by an ultrasonic flow probe (Transonic Systems Inc., Ithaca,
New York) built into the perfusate inflow tubing. As
previously shown (34), the perfusion system allowed main-
tenance of hearts in a steady state for at least 90 min, with
changes of less than 5% for all mechanical and metabolic
parameters.
A water-filled latex balloon was inserted into the LV
through an incision in the left atrial appendage, via the
mitral valve, and secured by a ligature. The balloon was
connected to a Statham P23Db pressure transducer (Gould
Instruments, Glen Burnie, Maryland) via a small-bore
polyethylene tubing for continuous measurement of left
ventricular pressure and heart rate on a four-channel re-
corder (Graphtec Corp., Tokyo, Japan). All hearts were
given 10 to 15 min for stabilization, where left ventricular
end-diastolic pressure was set to 10 mm Hg by adjusting the
balloon volume in the LV. A left ventricular pressure-
volume curve was performed by stepwise inflation of the
balloon by 0.03 ml until maximum left ventricular devel-
oped pressure (LVDP) was obtained or until end-diastolic
pressure (EDP) exceeded 50 mm Hg. Recordings of all
parameters were made at each step when a new steady state
was reached, which occurred within 2 min.
Serum estrogen levels. At the time of the excision of the
heart, blood was taken for hormone measurements. Serum
E2 levels were analyzed using a solid-phase
125I-
radioimmunoassay technique (DPC Bierman, Bad Nau-
heim, Germany) according to the manufacturer’s instruc-
tions. Assay sensitivity was 1.4 pg/ml for E2.
Determination of infarct size. The LV was shock-frozen
in methylbutane (Sigma GmbH, Deisenhofen, Germany)
precooled in liquid nitrogen. Hearts were then stored at
280°C. Sections of 14 mm were cut serially from apex to
base by a commercially available cryostat (Kryostat Mycro-
tom Jung CM 3000; Leica, Nussloch, Germany) at a
temperature of 226°C. Sections were stained for collagen
using Picrosirius Red (Sirius red: Chroma-Gesellschaft
Schmidt GmbH and Co., Ko¨ngen/N., Germany; picroacid:
E. Merck, Darmstadt, Germany). The scar extension,
clearly visible as red areas on each section, determines the
infarct area. Slices were digitized, and lengths of scar and
noninfarcted muscle for both endocardial and epicardial
surfaces were determined by cursor measurements for every
section. The ratio of the lengths of scar and surface
circumferences defined the infarct size for endo- and epi-
cardial surfaces, respectively. Final infarct size was deter-
mined as the average of endo- and epicardial surfaces and is
given as percentage of total heart size. To ensure compara-
bility of the infarcted groups, all hearts with an infarct size
,30% (n 5 12) and .50% (n 5 3) were excluded from the
analysis.
Statistical analysis. All data are presented as mean 6
standard error of the mean. With six experimental groups,
15 statistical comparisons are conceivable. Testing for this
high number of comparisons with multifactorial analysis of
variance would “overcorrect” significance levels. Therefore,
we limited the statistical analysis to “biologically meaning-
ful” comparisons, where each sham group is compared with
the respective MI group and to the altered hormonal status.
For example, the non-OVX 1 Sham group is compared
with non-OVX 1 MI, OVX 1 Sham and OVX 1 E2 1
Sham. Comparison of variables between two groups was
made by using the unpaired Student t test. Bonferroni’s
correction for multiple comparisons was applied to yield a
significance level of 0.05:3 5 0.017. Calculations were
performed by a commercially available program, Stat View
SE 1 Graphics (Brainpower Inc., Calabasas, California).
RESULTS
Animal characteristics and hormone determination. In-
farct size, body weight, tibial length, ex vivo heart weight
and estradiol serum levels are shown in Table 1. Mean
infarct size was 39 6 1% on average and was not different
among groups. Body weight was significantly higher in
OVX rats and significantly smaller in rats receiving chronic
E2 pellets compared with non-OVX animals. Also, tibial
length was significantly larger in OVX rats and smaller in
rats with E2 substitution compared with non-OVX animals.
Heart weight and heart weight/body weight increased in all
MI groups compared with sham-operated groups. Estrogen
Table 1. Characteristics of Study Groups and Hormone Levels
Non-OVX 1
Sham
Non-OVX 1
MI OVX 1 Sham OVX 1 MI
OVX 1 E2 1
Sham
OVX 1
E2 1 MI
n 11 11 12 11 15 13
MI size (%) — 39 6 2 — 39 6 2 — 40 6 2
BWafter (g) 273 6 9 264 6 3 346 6 7† 332 6 8† 223 6 6† 234 6 5†
TL (mm) 38.8 6 0.3 39.0 6 0.2 40.4 6 0.2† 39.8 6 0.6 36.3 6 0.4† 36.1 6 0.4†
HW (g) 1.41 6 0.12 2.30 6 0.20* 1.55 6 0.04 2.00 6 0.12* 1.17 6 0.20 1.86 6 0.11*
HW/BW (mg/g) 5.26 6 0.52 8.73 6 0.76* 4.43 6 0.08 5.90 6 0.32*† 5.27 6 0.81 8.17 6 0.59*
E2 (pg/ml) 49.0 6 10.8 40.2 6 10.8 11.3 6 3.6† 12.4 6 5.0† 92.0 6 12.7 74.8 6 17.9
*p , 0.017 sham vs. corresponding MI; †p , 0.017 non-OVX vs. OVX or OVX 1 E2.
BWbefore 5 body weight before OVX; BWafter 5 body weight 10 weeks after OVX; E2 5 estradiol serum level; HW 5 heart weight; MI 5 myocardial infarction; TL 5
tibial length.
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levels were significantly lower in the ovariectomized groups
and somewhat but not significantly higher in rats receiving
chronic E2 treatment compared with non-OVX animals.
Echocardiographic studies. M-mode tracings of the left
ventricular short axis from a non-OVX sham-operated, a
non-OVX with MI, an OVX with MI and an OVX 1 E2
rat with MI are shown in Figure 1. Echocardiographic
assessment of left heart geometry and function for the six
groups are shown in Table 2. Compared with sham-
operated hearts, MI hearts showed structural changes such
as increased LV diastolic and systolic diameters. Structural
changes after MI were unaltered when animals were OVX
or OVX 1 E2 treated. All MI groups showed enlarged left
atrium diameters indicating backward failure; this was also
unaffected by OVX or OVX 1 E2.
Functional abnormalities accompanied structural remod-
eling of the LV post-MI (Table 2). The combination of
impaired regional function and LV cavity enlargement
resulted in a substantial decrease in fractional shortening
(50 6 3% in sham vs. 19 6 2% in MI hearts; p , 0.0001).
These echocardiographic changes post-MI are as previously
reported (28). Modulation of hormonal status by OVX or
OVX 1 E2 had no effect on echocardiographic indices of
cardiac function in infarcted hearts.
Doppler-derived indices of systolic and diastolic function
are shown in Table 2. Myocardial infarction caused alter-
ations of LV diastolic filling indicated by a “restrictive
pattern,” that is, a decreased mitral A/E ratio (0.20 6 0.09
and 0.61 6 0.11 for non-OVX 1 MI vs. non-OVX 1
Sham). These parameters were unchanged by OVX or
OVX 1 E2. In spite of functional and structural alterations,
under the unstressed conditions studied here, all groups
maintained normal cardiac output (in absolute as well as in
relative terms).
In vivo hemodynamics. In vivo hemodynamic parameters
of the six groups are shown in Table 3. Hemodynamic
changes of MI groups were characteristic of post-MI
remodeling in the rat model (26,35): EDP increased,
whereas HR, systolic LV pressure and mean arterial pres-
sure were unchanged. The hormonal status did not affect in
vivo hemodynamics.
In vitro cardiac performance and pressure-volume rela-
tions. Figure 3 shows LVDP-volume relations for the six
experimental groups. The curve for the non-OVX 1 MI
group was shifted right and downwards, indicating struc-
tural dilation and left ventricular dysfunction. Pressure-
volume curves were not significantly affected by OVX or
OVX 1 E2 treatment.
DISCUSSION
Definition of the model. The present study defines cardiac
dimensions and function under estrogen deficiency caused
by bilateral ovariectomy and under E2 repletion, mimicking
a postmenopausal hormonal status as well as the effects of
estrogen replacement therapy and using a clinically highly
relevant model of heart failure occurring chronically post-
MI. For non-OVX sham and MI groups, in vivo and in
vitro findings were as previously reported (33,36,37). In MI
hearts, structural dilation is indicated by increased left
Table 2. M-Mode and Doppler Echocardiographic Data
Non-OVX 1
Sham
Non-OVX 1
MI
OVX 1
Sham OVX 1 MI
OVX 1 E2 1
Sham
OVX 1
E2 1 MI
LV diast diam (mm) 6.7 6 0.2 8.9 6 0.4* 7.7 6 0.2 9.1 6 0.2* 6.9 6 0.1 8.9 6 0.3*
LV diast diam/TL 0.17 6 0.01 0.23 6 0.01* 0.19 6 0.01 0.23 6 0.01* 0.19 6 0.00 0.25 6 0.01*
LV syst diam (mm) 3.4 6 0.3 7.2 6 0.4* 4.1 6 0.3 7.0 6 0.3* 3.6 6 0.2 6.7 6 0.4*
LV syst diam/TL 0.09 6 0.01 0.19 6 0.01* 0.10 6 0.01 0.18 6 0.01* 0.10 6 0.01 0.19 6 0.01*
LV FS (%) 49.9 6 3.4 19.3 6 2.1* 46.7 6 2.9 23.2 6 2.4* 48.4 6 3.0 25.6 6 2.4*
Left atrium (mm) 3.8 6 0.2 5.4 6 0.5* 4.3 6 0.3 6.2 6 0.3* 3.6 6 0.2 4.9 6 0.3*
Cardiac output (ml/min) 92 6 18 81 6 13 96 6 10 85 6 10 71 6 7 58 6 8
Cardiac index (ml/min/kg) 344 6 62 315 6 51 277 6 25 259 6 30 316 6 24 245 6 33
Mitral-A/E ratio 0.61 6 0.11 0.20 6 0.09* 0.57 6 0.04 0.33 6 0.08* 0.52 6 0.03 0.32 6 0.07*
*p , 0.017 sham vs. corresponding MI; †p , 0.017 non-OVX vs. OVX or OVX 1 E2.
diam 5 diameter; diast 5 diastolic; FS 5 fractional shortening; LV 5 left ventricular; syst 5 systolic; TL 5 tibial length.
Table 3. In Vivo Hemodynamics
Sham MI OVX 1 Sham OVX 1 MI E2 1 Sham E2 1 MI
Heart rate (beats/min) 394 6 13 360 6 11 368 6 11 361 6 11 361 6 11 344 6 13
LVSP (mm Hg) 137 6 8 126 6 5 128 6 4 125 6 5 118 6 4 118 6 4
LVEDP (mm Hg) 8 6 2 23 6 4* 8 6 1 18 6 3* 7 6 2 20 6 3*
MAP (mm Hg) 110 6 7 91 6 6 103 6 3 98 6 4 93 6 2 95 6 4
*p , 0.017 sham vs. corresponding MI; †p , 0.017 non-OVX vs. OVX or OVX 1 E2.
EDP 5 end-diastolic pressure; LV 5 left ventricular; MAP 5 mean aortic pressure; SP 5 systolic pressure.
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ventricular and left atrial diameters measured in vivo and
rightward shift of pressure-volume curves ex vitro. De-
creased systolic function is demonstrated by decreased
fractional shortening (in vivo) and downward shift of the
pressure-volume curves (ex vivo). In addition, diastolic
dysfunction is attested to by increased left ventricular EDP
and an abnormal left ventricular filling pattern (A/E wave).
The model used here is well suited to study the chronic
effects of both protective (37–39) and deleterious (40)
interventions. Thus, with the number of experimental
animals used here, this model would allow detection of
major effects of estrogen status on the remodeling process, if
such effects were present.
Effects of OVX and of estrogen replacement. The major
finding of the present study was that estrogen deficiency
occurring after OVX does not have a major adverse effect on
the remodeling process post-MI. In OVX rats, estradiol
serum levels were still detectable but were significantly
(approximately fourfold) reduced compared with non-OVX
rats. This hormonal status is similar to that found in
postmenopausal women, because nonovarian sources con-
tribute to circulating estradiol levels to a small extent. The
biological efficacy of OVX in this study is, next to decreased
estradiol serum levels, demonstrated by increased body
weight and increased tibial length, both abolished by E2
replacement. These effects of estrogen deficiency are well
characterized (41–45) and correspond to the weight gain at
the time of menopause (46).
In infarcted non-OVX animals, hearts developed sub-
stantial hypertrophy, as indicated by increased heart weight
occurring in spite of the loss of approximately 40% of left
ventricular tissue from infarction. Ovariectomy did not
modulate the extent of hypertrophy, as attested to by similar
heart weight and heart weight/tibial length ratios. The same
was true for estrogen replacement after OVX. In this model,
neither ovariectomy nor estrogen replacement had any effect
on geometry or function in either sham-operated or in-
farcted hearts. Post-MI, the increase of left ventricular
diastolic and systolic dimensions and decrease of fractional
shortening were all similar for the three MI groups. Dia-
stolic function was impaired to the same extent in all MI
groups with increased left atrial dimensions, decreased
mitral A/E ratios and increased left ventricular end-diastolic
pressures in vivo. In vitro pressure-volume relations, show-
ing a marked right and downward shift in the infarcted
groups, were also unaffected by the hormonal status. Al-
though a trend to higher developed pressures was observed
post-MI in the estrogen replacement group, this finding did
not reach statistical significance. In this study, we used a
slightly supraphysiologic estrogen replacement dosage. It
remains possible, however, that a protective effect of estro-
gens can be detected when higher, pharmacologic doses are
used. Data in this respect are currently lacking, and this
hypothesis merits testing.
Epidemiological findings in postmenopausal women led
us to examine whether endogenous estrogen deficiency
affects the remodeling process post-MI. The Framingham
Study (1) addressed gender differences in cardiovascular
morbidity and mortality over age. Premenopausal women
seem to be protected from cardiovascular disease, whereas
the risk of MI rises dramatically after menopause, resulting
in a lifetime risk that is similar to that of men. Conversely,
clinical studies (7–12) have shown that women have a
higher mortality after MI compared with men. Estrogens
may affect the extent of cardiovascular disease not only by
their systemic actions, that is, altered lipid profile and
lowering of blood pressure, but also by direct effects on the
vascular wall, especially on vascular smooth muscle cells. In
an experimental study, estrogen has been shown to inhibit
the response to vascular injury in the mouse carotid artery,
even without alterations in the systemic lipid profile (47).
However, not only the vascular tissue but also the heart is a
target organ for estrogen action. Cardiac myocytes and
fibroblasts express functionally intact estrogen receptors
(25). These are the major cells contributing to left ventric-
ular hypertrophy. Clinical trials have shown that, indeed,
women have a lower prevalence of left ventricular hypertro-
phy than men (48,49). The Framingham Heart Study
showed that left ventricular mass is significantly greater in
men than in women, even after indexing for body surface
area. Farhat et al. (50) demonstrated in a rat model of
pulmonary hypertension that OVX potentiates the extent of
right ventricular hypertrophy, and, in sinoaortic denervated
rats, Cabral et al. (51) demonstrated the inhibition of left
ventricular hypertrophy development by estrogen. By con-
trast to these results, however, our findings clearly suggest
that physiological concentrations of E2 do not have major
effects on the remodeling process post-MI. The reason for
these discrepancies are, at present, unclear but may be
related to model-specific causes of hypertrophy (right vs. left
heart, pressure vs. volume overload, etc.).
The discrepancy between clinical observations and the
results of the present study may be explained by the design
of epidemiologic studies. A recent clinical trial by Malacrida
et al. (52) confirmed an increased mortality in women after
a cardiovascular event compared with men. However, in this
study, women were, on average, older than men. Adjust-
ment for age and other differences of baseline clinical
features reduced the difference to a nonsignificant relative
risk of 1.1. Sonke et al. (53) showed higher case fatality for
women after hospital admission compared with men, but,
after adjustment for confounding variables, this increase was
reduced to a relative risk of 1.18. They concluded that the
higher case fatality after an acute cardiac event in women
admitted to the hospital may largely be explained by
differences in living status, history and medical treatment
and is balanced by a lower case fatality before admission. It
is, therefore, possible that the cardioprotective effects of
estrogen are related to endothelial function, acute cardiac
arrhythmias and reduction of infarct size. These effects were
not examined in the present study, because hearts were
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selected to yield similar mean infarct sizes among the MI
groups. This is a requirement if the chronic effects of
interventions on post-MI remodeling are to be tested (35).
The assumption that possible beneficial effects of estrogen
are related to the acute/subacute stage of MI is supported by
the observation that increased mortality in postmenopausal
women is largely restricted (54,55) to in-hospital mortality.
However, the new randomized trial Heart and Estrogen-
progestin Replacement Study (HERS) (56) showed no
reduction in the overall rate of coronary heart disease
(CHD) events in postmenopausal women with established
CHD during an average follow-up of 4.1 years, treating
patients with oral conjugated equine estrogen plus medroxy-
progesterone acetate. The risk of CHD events was increased
in the early phase of hormone replacement therapy but
decreased after several years of therapy. The results of this
study cannot directly be extrapolated to our findings; how-
ever, the design of HERS was chosen to demonstrate a
secondary prevention of CHD with hormone replacement
therapy. By contrast, the purpose of our study was to show
alterations in post-MI remodeling.
Study limitations. We induced estrogen deficiency by
bilateral ovariectomy. Therefore, estradiol serum levels
were low but still detectable, similar to the menopausal
situation. We do not know whether additional blockade of
estrogen receptors by estrogen receptor antagonists (e.g.,
ICI182,780) may cause a detrimental effect on cardiac
remodeling. However, this situation would be clinically less
relevant. Moreover, we did not examine whether adminis-
tration of pharmacological doses of estrogen may positively
influence chronic cardiac structural and functional alter-
ations. These studies remain to be done.
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